Scientific Program
Full Interactive Program
The meeting will officially run on Central European Summer Time (CEST), GMT +2.
To convert the meeting times to your local time Click Here
Program Highlights
Plenary Sessions
- How the discovery of antiphospholipid antibodies has changed lupus life
- When should we use the new drugs in lupus nephritis?
- Antimalarials are useful but rather weak medications for SLE
- How common is clinical remission in the real life? Experience from all around the world
- The time has come to set up diagnostic criteria in SLE?
- Is it safe to withdraw a low-dose-glucocorticoid in SLE patients in remission?
- When should targeted therapies be used in the treatment of lupus nephritis?
Parallel Sessions (CORA)
- Debate: Autoimmunity and autoinflammation
- Debate: Systemic sclerosis
- Debate: Rheumatoid arthritis
- Debate: Systemic sclerosis 2
- Debate: Spondyolarthritis
- Dedicated COVID/Vaccination session
- COVID/Vaccination debate
- Debate: Sjögren syndrome
- Debate: Rheumatoid arthritis
- Debate: Autoimmunity and autoinflammation
- Debate: Spondyolarthritis
- Debate: Vasculitis
Live Meet the Professor Sessions (CORA)
- Jak-inhibitors in rheumatoid arthritis
- Autoinflammatory diseases
- Biologics: on and off-label use
- Cannabis: a friend or a foe?
- Systemic sclerosis: what is new?
Live Interactive Workshops
- Lupus nephritis
- Cutaneous lupus lesions
- Anti-Rheumatic treatment before and during pregnancy
- Cardio-pulmonary manifestations
- Management of lupus pregnancies
- Cardio-pulmonary manifestations
- Neuropsychiatric lupus
- Musculoskeletal manifestations in SLE
Parallel Sessions (LUPUS)
- Pathogenic insights and implications for treatment
- Disease activity and outcome measures in SLE
- NeuroSLE
- Arthritis, vaccines and COVID-19 in SLE
- Precision and personalized Medicine
- Cardiovascular (and vascular) risk management
- Early SLE
- Antiphospholipid antibody syndrome and SLE
- Biomarkers
- Pipeline molecules in SLE
- Lupus nephritis – clinical aspects
- New clues in SLE pathogenesis
- How do we integrate available biologics in SoC?
- Skin
- New clues in LN pathogenesis
- Difficult-to-manage SLE manifestations
- Management of SLE: what are we missing?
- Pregnancy
Live Meet the Professor Sessions (SLE)
- Biologics in SLE
- Comorbidities and SLE
- The standard of care in SLE
- Molecules in the development in SLE therapy
- Unmet needs in SLE: how do we assess it?
- What should we measure in clinical practice in SLE patients?
- Molecules in the development in SLE therapy
- The standard of care in SLE
- Why is everything autoimmune until proven otherwise?